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patients. Minimal artifacts that did not compromise diagno-
sis were noted in 4/62 patients.
Conclusion Low-dose gadobenate dimeglumine-
enhanced MRI is effective for the differential diagnosis of 
malignant renal tumors.
Keywords Gadobenate dimeglumine · Kidney · Renal 
MRI · Renal cell carcinoma
Introduction
Although renal cell carcinoma (RCC) is the most common 
malignant epithelial tumor of the kidney accounting for 
85–90 % of all solid renal tumors in adults and represent-
ing 5 % of all cancers in men and 3 % in women [1, 2], 
benign solid neoplasms such as angiomyolipoma (AML) 
and oncocytoma represent 10–14 % of all resected solid 
renal tumors [3–5]. A major clinical need therefore is to 
accurately differentiate RCC and other malignant renal 
lesions which typically require urgent surgical attention 
from benign solid neoplasms for which conservative man-
agement is usually indicated.
Whereas contrast-enhanced ultrasound (CEUS; [6–8]) 
and multi-detector-computed tomography (MDCT; [9–11]) 
are frequently first-line imaging techniques that reveal the 
presence of renal masses, often incidentally, subsequent 
work-up of patients with suspected malignant renal disease 
is usually performed using contrast-enhanced MR imaging 
(CE-MRI) because of the wide versatility of this technique 
and its ability to accurately identify fat within renal tumors. 
Several studies have demonstrated the effectiveness of CE-
MRI not only for the differential diagnosis of renal tumors 
but also for the accurate differentiation of different RCC 
sub-types [12–19].
Abstract 
Objective To evaluate low-dose gadobenate dimeglu-
mine-enhanced MRI for the differential diagnosis of malig-
nant renal tumors.
Methods Sixty-two consecutive patients with unclear 
diagnosis at MDCT/ultrasound underwent dynamic CE-
MRI of the kidneys with 0.05 mmol/kg gadobenate dime-
glumine. Retrospective image evaluation was performed by 
two blinded readers. Lesion diagnosis at CE-MRI was cor-
related with findings from histology following tumor resec-
tion or from imaging follow-up after at least 1 year. Assess-
ments were performed of diagnostic quality and level of 
diagnostic information.
Results Thirty-nine (63 %) patients were correctly diag-
nosed with malignant lesions (36 with RCC, 2 with renal 
metastases, 1 with lymphoma) while 14 (22.6 %) patients 
were correctly diagnosed with benign (n = 12) or no 
(n = 2) lesions. Eight patients were considered false posi-
tive (5 with oncocytoma, 3 with atypical AML) and 1 
patient false negative (atypical RCC). The sensitivity, spec-
ificity, accuracy, PPV, and NPV for the diagnosis of malig-
nant renal lesions were 97.5 % (39/40), 63.6 % (14/22), 
85.5 % (53/62), 83.0 % (39/47), and 93.3 % (14/15), 
respectively. Images were excellent in 60 and good in 2 
 * Guenther Schneider 
 dr.guenther.schneider@uks.eu
 Miles A. Kirchin 
 miles.kirchin@bracco.com
1 Department of Diagnostic and Interventional Radiology, 
Saarland University Medical Center, 66421 Homburg/Saar, 
Germany
2 Global Medical and Regulatory Affairs, Bracco Imaging 
SpA, Milan, Italy
1101Radiol med (2015) 120:1100–1111 
1 3
To date, most recent protocols for CE-MRI of the kidney 
have utilized gadolinium-based contrast agents (GBCAs) 
at a dose of at least 0.1 mmol/kg bodyweight [13–18]. 
Moreover, the contrast agents used have invariably been 
conventional GBCAs such as gadopentetate dimeglumine 
which have standard r1 relaxivity values of approximately 
4.2 L mmol−1 s−1 at 1.5 T [20]. The aim of our study was 
to retrospectively determine the diagnostic performance 
of CE-MRI for the accurate diagnosis of malignant renal 
masses using a lower dose (0.05 mmol/kg BW) of the much 
higher relaxivity GBCA gadobenate dimeglumine (Multi-
Hance; Bracco Imaging SpA, Milan, Italy).
Methods and materials
Patients
Between January 2008 and December 2013, 184 consecu-
tive patients at our institution underwent abdominal CE-
MRI with 0.05 mmol/kg BW gadobenate dimeglumine 
with specific emphasis on dynamic CE-MRI of the kidneys. 
Of these 184 patients, 122 (66.3 %) underwent CE-MRI 
for follow-up of prior surgical resection of known malig-
nant lesions or for routine-scheduled follow-up of known 
benign lesions. The remaining 62 (33.7 %) patients under-
went CE-MRI because of equivocal renal tumors detected 
at multiphasic MDCT or ultrasound. This retrospective 
assessment focuses on these 62 patients. Institutional 
review board approval was obtained for the study. Written 
informed consent for the use of individual patient imaging 
data for research purposes was obtained from all patients.
The 62 evaluated patients included 37 men (mean age 
58.5 ± 16.1 years; age range 10–79 years) and 25 women 
(mean age 62.5 ± 11.9 years; age range 37–80 years) 
with an overall mean age of 60.1 ± 14.8 years (age range 
10–80 years).
MR imaging
MR imaging examinations were performed at 1.5 Tesla 
(Magnetom Vision, Sonata or Aera; Siemens Medical 
Systems, Erlangen, Germany). Patients were imaged in 
the supine position using a surface phased-array coil and 
the following sequences: (a) coronal T2-weighted half-
Fourier single-shot fast spin-echo [repetition time (TR) 
ms/echo time (TE) ms, 800–1100/60–92; section thick-
ness, 5 mm; gap, 1 mm; matrix, 192 × 256; flip angle, 
155°–180°; field of view (FOV), 35–45 cm], (b) axial dual-
echo T1-weighted in-phase and opposed-phase gradient-
echo (130–205/2.2–2.7, 4.5–5.2; flip angle, 70°; section 
thickness, 5 mm; gap, 1 mm; matrix, 160 × 256; FOV, 
35–45 cm). For contrast-enhanced imaging, a dynamic 
T1-weighted gradient-echo sequence (160–210/4.5–4.8; 
flip angle, 70°; slice thickness, 5–6 mm; gap, 1 mm; matrix 
154–180 × 256; FOV, 35–45 cm) was used when using a 
Siemens Magnetom Vision or Sonata. In the equilibrium 
phase, a T1w gradient-echo sequence with chemically 
selective fat saturation was acquired (134–160/2.3–2.7; flip 
angle, 70°; slice thickness, 5 mm; gap, 1 mm; matrix 154–
195 × 256–320; FOV, 35–45 cm). With the Magnetom 
Aera system volume-interpolated breath-hold examinations 
(VIBE) were performed for both unenhanced and contrast-
enhanced imaging. A Dixon T1w sequence with the fol-
lowing parameters was acquired: TR 6.77 ms; TE 2.38 ms; 
slice thickness 3 mm; FOV, 380 mm2; breath-hold acqui-
sition time 21 s, permitting acquisition of the following 4 
T1w images at each slice level: in-phase image (standard 
T1), opposed-phase image, water-only image (fat sup-
pressed T1), fat-only image.
Contrast-enhanced T1-weighted gradient-echo acquisi-
tions were obtained dynamically in the cortico-medullary 
and nephrographic phases after administration of a bolus 
of 0.05 mmol/kg bodyweight of gadobenate dimeglumine 
at a rate of 2 mL/s followed by a 20-mL saline flush. For 
early examinations, the first pass was timed to the cortico-
medullary phase by best guess (25 s post-start of contrast 
injection) while the nephrographic phase was acquired 
at approximately 5 min post-contrast injection. With the 
newer VIBE sequences, multiple phases were acquired and 
the appropriately timed sequences were chosen from the 
acquired data.
Routine diffusion-weighted imaging (DWI) for patients 
with suspected RCC was introduced into our department in 
September 2010 when the Magnetom Aera was installed. 
Of the 62 patients included in this assessment, DWI was 
performed for 29 patients using an echo planar imaging-
spin echo (EPI-SE) sequence with free breathing. The 
parameters for DWI acquisitions were as follows: TR/
TE [ms] = 6400/68, section thickness, 6 mm; gap, 0 mm; 
number of slices, 35; matrix, 192 × 156; averages, 3; 
FOV [mm × mm], 380 × 308; spatial resolution [mm3], 
2.0 × 2.0 × 5.0; b values [s/mm2], 0, 400, 800; bandwidth 
[Hz/px], 1735; acquisition time [min], 4:30. Parallel imag-
ing (GRAPPA 2) and fat suppression (SPAIR) were used.
Image evaluation
CE-MRI images were acquired as part of routine clinical 
practice. Based on CE-MRI diagnosis in conjunction with 
available findings from prior diagnostic imaging studies, 
patients were referred either for surgical resection of the 
detected lesion(s) or for conservative management. Typi-
cally, lesions that show no evidence of homogeneous fat 
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distribution on unenhanced MR images but which dem-
onstrate contrast enhancement following contrast admin-
istration are malignant in nature. Occasionally, RCC may 
present with minimal fat in just one area of the lesion. For 
the purposes of this study, lesions that demonstrated either 
of these features were considered malignant. Final lesion 
diagnosis was based on the histopathologic results for the 
specimen obtained at surgical resection or on imaging fol-
low-up obtained after at least 1 year.
Subsequent retrospective evaluation of images was 
performed qualitatively by two readers (PF, AB; 8 and 
15 years’ experience in abdominal MRI, respectively) in 
consensus who were not involved in the conduct of the 
studies and who were fully blinded to the clinical history 
of the patients, the results of all diagnostic imaging exami-
nations, and to the final clinical diagnosis. Assessments 
were performed in terms of quality of kidney visualiza-
tion (insufficient, poor, moderate, good, excellent), pres-
ence of artifacts (severe, moderate, minimal, none), extent 
of diagnostic information (unsatisfactory, partial, satisfac-
tory, complete), and overall diagnostic value (limited, sat-
isfactory, high). Additional assessments were performed of 
lesion size and of any additional diagnostic information.
Statistical analysis
Diagnostic performance for the characterization of lesions 
as malignant or benign was performed at the patient level 
for all 62 patients using CE-MRI images plus unenhanced 
axial dual-echo T1-weighted in-phase and opposed-phase 
gradient-echo images for the analysis of fat content. For 
this evaluation, patients diagnosed with malignant renal 
lesions at CE-MRI which were confirmed as malignant at 
final diagnosis were considered true positive (TP) while 
patients diagnosed with benign renal lesions or no lesions at 
CE-MRI which were confirmed as benign or absent at final 
diagnosis were considered true negative (TN). Patients with 
renal lesions diagnosed as malignant at CE-MRI which 
were confirmed as benign at final diagnosis were consid-
ered false positive (FP) while patients with renal lesions 
diagnosed as benign at CE-MRI which were confirmed as 
malignant at final diagnosis were considered false negative 
(FN). Based on these findings, determinations were made 
of the sensitivity, specificity, accuracy, positive predictive 
value (PPV), and negative predictive value (NPV) of CE-
MRI with 0.05 mmol/kg gadobenate dimeglumine for the 
diagnosis of malignant renal tumors.
Results
Based on CE-MRI findings alone, 39/62 (63 %) patients 
were diagnosed with malignant renal lesions. These 
39 patients included 29 with RCC confirmed at histol-
ogy (Figs. 1, 2), 7 patients with RCC confirmed at imag-
ing follow-up, 2 patients with renal metastases confirmed 
at histology (in patients with primary lung cancer and 
breast cancer), and 1 patient with lymphoma confirmed at 
imaging follow-up. The 29 RCC confirmed at histology 
included 20 clear cell tumors, 6 papillary tumors, 1 mixed 
clear cell/papillary tumor, and 2 chromophobe tumors. 
These 39 patients were considered TP for renal cancer. A 
further 14/62 (22.6 %) patients were diagnosed with benign 
(n = 12) or no (n = 2) renal lesions. The 12 patients with 
benign lesions included 8 with complicated renal cysts con-
firmed at imaging follow-up (n = 7) or histology (n = 1), 
3 patients with AML confirmed at imaging follow-up 
[including one 10-year-old boy with multiple bilateral 
AML (Fig. 3), one of which was resected due to its rapid 
growth and risk of hemorrhage], and 1 patient diagnosed 
with inflammatory tumor (Fig. 4) which was confirmed at 
imaging follow-up (pyelonephritis with renal abscess for-
mation, which completely resolved under antibiotic ther-
apy). These 14 patients were considered TN for malignant 
renal tumors. The remaining 9 patients included 8 patients 
that were diagnosed with malignant lesions (n = 7) or an 
unspecified lesion (n = 1) at CE-MRI which were con-
firmed as benign [oncocytoma in 5 patients (Fig. 5), atypi-
cal AML in 3 patients] at either histology (n = 6) or imag-
ing follow-up (n = 2). One of these patients was diagnosed 
with both an RCC and AML which were confirmed as two 
AML at histology. These 8 patients were considered FP for 
malignant renal tumors. The final patient was considered to 
have an unspecific lesion at CE-MRI which was confirmed 
as an atypical RCC at histology. Based on its appearance 
at CE-MRI (solid, hypovascular, showing almost no con-
trast uptake, and without characteristic features of a benign 
lesion), the lesion was recommended for resection. Nev-
ertheless, for the purposes of this study, since a malignant 
diagnosis was not made at CE-MRI, this patient was con-
sidered FN for malignant renal tumors.
The overall mean size of lesions was 27.1 ± 20.6 mm 
(range: 4–94 mm). The overall mean size of lesions diag-
nosed as malignant (27.6 ± 21.6 mm; range: 4–94 mm) 
was slightly larger than those diagnosed as benign 
(17.3 ± 16.2 mm; range: 4–67 mm).
Based on a total of 39 TP patients, 14 TN patients, 8 FP 
patients, and 1 FN patient, the overall sensitivity, specific-
ity, accuracy, PPV, and NPV were determined to be 97.5 % 
(39/40), 63.6 % (14/22), 85.5 % (53/62), 83.0 % (39/47), 
and 93.3 % (14/15), respectively, for the diagnosis of renal 
cancer on CE-MRI with 0.05 mmol/kg gadobenate dime-
glumine. No gender-based differences were apparent: the 
sensitivity, specificity, accuracy, PPV, and NPV for male 
patients [95.6 % (22/23), 71.4 % (10/14), 86.5 % (32/37), 
84.6 % (22/26), and 90.9 % (10/11)] were similar to that of 
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female patients [100 % (17/17), 50 % (4/8), 84 % (21/25), 
80.9 % (17/21), and 100 % (4/4)].
Among the 37 patients with confirmed RCC (36 TP 
patients plus 1 FN patient), additional findings in the liver 
were noted in 6 patients [metastases in 3 patients (Fig. 6), 
hemangiomas in 3 patients].
Blinded qualitative evaluation
The quality of kidney visualization was rated as excellent 
in 60 patients and as good in 2 patients. In no patient was 
the quality of visualization considered insufficient, poor, 
or moderate. Images were completely free of artifacts in 
58 patients; in the remaining 4 patients, minimal artifacts 
were noted which did not compromise image interpre-
tation or diagnosis. The necessary imaging information 
needed to make a diagnosis was considered complete in all 
62 patients; the value of this diagnostic information was 
considered high in 61 patients and satisfactory in just one 
patient.
Discussion
An early prospective assessment of the diagnostic perfor-
mance of CE-MRI for the differentiation of patients with 
malignant renal lesions from patients with benign renal 
lesions determined values for sensitivity, specificity, PPV, 
and NPV of 93.8 % (15/16), 66.7 % (8/12), 78.9 % (15/19), 
and 88.8 % (8/9), respectively [9]. In that study, all onco-
cytomas were falsely classified as carcinomas (FP lesions) 
while three AMLs and three inflammatory lesions were cor-
rectly classified as benign (TN lesions) resulting in an over-
all per-patient-based accuracy of 82.1 % (23/28). In com-
mon with other studies focused on the CE-MRI evaluation 
of renal masses [13–18], the study utilized a conventional 
GBCA at a dose of 0.1 mmol/kg bodyweight [9]. Our ret-
rospective study, performed as part of routine clinical prac-
tice in patients referred for abdominal/renal MRI because 
of unclear findings on multiphasic MDCT, utilized gado-
benate dimeglumine at a dose of only 0.05 mmol/kg bod-
yweight. Our values for sensitivity, specificity, accuracy, 
Fig. 1  Renal cell carcinoma with a tumor thrombus in the left renal 
vein and IVC. The T2w HASTE sequence (a) reveals a small lesion 
in the left kidney (arrow) together with enlargement of the left renal 
vein, filled with material that is isointense to the normal renal paren-
chyma (arrowhead). On the corresponding T1w image (b) the tumor 
is hyperintense and no flow void is visible within the left renal vein. 
After injection of gadobenate dimeglumine at a dose of 0.05 mmol/kg 
BW the tumor and left renal vein show inhomogeneous enhancement 
in the early phase (c) with early contrast wash-out in the later phase 
(d). This enhancement suggests a RCC with a tumor thrombus in 
the left renal vein. Note the complete occlusion of the IVC (e), with 
the IVC completely filled with solid tumor material from the tumor 
thrombus (arrow in e)
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PPV, and NPV of 97.5 % (39/40), 63.6 % (14/22), 85.5 % 
(53/62), 83.0 % (39/47), and 93.3 % (14/15), respec-
tively, bear excellent comparison with those of the above 
study [9]. Although comparison with a full dose of another 
GBCA was not performed in our study, our results suggest 
that equivalent diagnostic performance might be achieved 
with just half the amount of gadolinium if gadobenate 
dimeglumine is the utilized GBCA. In this regard, a previ-
ous intra-individual crossover comparison of 0.05 mmol/kg 
gadobenate dimeglumine with 0.1 mmol/kg gadopentetate 
dimeglumine in patients undergoing CE-MRI of the liver 
revealed clear equivalence during the dynamic phase of 
Fig. 2  Renal cell carcinoma. On the T2w HASTE sequence (a) a 
hyperintense lesion (arrow) is visible in the right kidney. On the 
VIBE sequence with acquisition of in-phase, opposed-phase, and 
Dixon fs-images (b–d) in one single breath-hold, the lesion demon-
strates a hypointense rim on the in-phase image (b), some hypoin-
tense areas in the center on the opposed-phase image (c) indicating 
fat within the tumor, and a homogeneous hypointense signal in the 
fat suppressed image (d). The diffusion-weighted images and the 
ADC-map (e; b = 50, 400, 800 +ADC from left to right) reveal 
restricted diffusion and a hypointense appearance of the tumor in 
the ADC-map. Dynamic contrast-enhanced fs VIBE-sequences (f–k) 
(0.05 mmol/kg gadobenate dimeglumine) demonstrate tumor hyper-
vascularity with early contrast wash-out. All findings indicate a RCC 
which was proven on histology after partial nephrectomy
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contrast enhancement with significant superiority for gado-
benate dimeglumine during the delayed hepatobiliary phase 
[21].
Clearly, these findings are potentially very important 
given the risk of nephrogenic systemic fibrosis (NSF) in 
patients with severe renal insufficiency given the possibil-
ity of compromised renal function in patients with renal 
tumors and the fact that new-onset post-operative chronic 
kidney disease (CKD) is a relatively frequent occurrence 
in patients undergoing curative surgery for renal cell carci-
noma, particularly in patients aged 60 years or older and in 
patients with already decreased preoperative renal function 
[22–26]. In this regard, although symptoms of NSF typi-
cally manifest within approximately 3 months of GBCA 
administration, longer lead-times are not unknown [27, 
28]. Notably, no unconfounded cases of NSF have yet been 
reported for gadobenate dimeglumine despite its regular 
use in patients at heightened risk of developing this disease 
[29–32]. As reported elsewhere for a variety of MR indica-
tions [21, 33–40], the possibility to use a reduced dose of 
gadobenate dimeglumine reflects the higher r1 relaxivity of 
this agent (6.2 vs. 3.9–4.6 L mmol−1 s−1 at 1.5 T according 
to recent data [20]) which derives from weak, transient 
interaction of the Gd-BOPTA contrast-effective molecule 
with serum albumin [41, 42] and a resulting slowing of the 
molecular tumbling rate which leads to greater shortening 
of the T1 relaxation time and thus greater signal enhance-
ment at equivalent dose [43].
Unlike conventional GBCAs which are excreted almost 
exclusively via the kidneys, approximately 2–4 % of the 
injected dose of gadobenate dimeglumine is eliminated 
via the hepatobiliary pathway [44, 45]. Although this level 
of hepatobiliary excretion does not alter the pharmacoki-
netic profile of gadobenate dimeglumine relative to the 
profiles of conventional GBCAs [44, 45] or the character-
istic dynamic enhancement patterns of frequently encoun-
tered tumors in the liver [46–51] and breast [52–55], it is 
sufficient to permit delayed hepatobiliary phase imaging 
of the liver for the improved detection and characteriza-
tion of liver lesions [46–51]. On the one hand, the simi-
lar dynamic enhancement behavior of gadobenate dime-
glumine relative to conventional GBCAs, even at half the 
dose [21], may explain the similar diagnostic performance 
of gadobenate dimeglumine for renal MRI not only in 
Fig. 2  continued
1106 Radiol med (2015) 120:1100–1111
1 3
terms of the accurate detection of malignant lesions but 
also the accurate differentiation of malignant from benign 
lesions. In this regard, the FP lesions detected in our study 
(5 oncocytoma, 3 atypical AML i.e., AML without vis-
ible fat) are typical of the FP lesions detected elsewhere 
[9, 15, 17–19, 56, 57]. Both of these benign lesions share 
Fig. 3  Multiple angiomyolipoma. The T2w HASTE sequence (a) 
shows a large mass (arrow) in the right kidney with heterogeneously 
distributed fat throughout. On the corresponding T1w image (b) the 
tumor shows areas of increased signal intensity, indicating either fat 
or hemorrhage within the tumor. The areas of increased signal on the 
T1w image are hypointense on the opposed-phase image (c) and the 
T1w fs image (d), indicating fat within the tumor. After injection of 
0.05 mmol/kg gadobenate dimeglumine, the lesion shows inhomoge-
neous but strong vascularization in the early arterial phase (e) with 
early wash-out in the later phase (f). In the fat suppressed image in 
the equilibrium phase (g) additional lesions (arrows) are visible that 
are hypointense compared with the normal renal parenchyma. Taken 
together these findings indicate multiple angiomyolipoma, which 
were proven after nephron sparing surgery of the largest lesion (per-
formed because of the risk of bleeding)
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many radiologic features with certain types of RCC [12, 
18, 58] making accurate and consistent differentiation 
challenging. Atypical AML without visible fat accounts 
for approximately 5 % of all AMLs [18, 56], while onco-
cytomas account for approximately 3–7 % of all adult 
renal neoplasms [59]. On the other hand, the additional 
possibility to acquire delayed hepatobiliary phase images 
of the liver during the same imaging session may be of 
value for patients diagnosed with aggressive and poten-
tially metastatic RCC or with other incidental findings 
detected during the initial dynamic acquisition. In our 
study, 3/37 patients with RCC presented with additional 
liver metastases. Although in all cases these findings were 
noted on dynamic phase acquisitions of the liver as hyper-
vascular lesions, reflecting the typical enhancement pat-
tern of metastases from RCC, such patients may benefit 
from an additional hepatobiliary phase exam at no extra 
cost or inconvenience and with no additional GBCA 
administration, particularly given that as many as 30 % 
of patients with RCC present with metastases [60–62] 
and that metastatic RCC has a relatively poor prognosis 
(5-year survival rate approximately 20 % [63, 64]). Sev-
eral studies have shown that hepatobiliary phase imag-
ing with gadobenate dimeglumine improves the detec-
tion of hepatic metastases relative to that achievable 
with other techniques [65–67]. A further 3 patients with 
RCC in our study had liver hemangiomas detected inci-
dentally during dynamic phase imaging. Characterization 
of these lesions and differentiation from liver metastases 
was correctly achieved in all cases reflecting the suitabil-
ity of gadobenate dimeglumine for liver imaging. In this 
regard, gadobenate dimeglumine is specifically approved 
in Europe and elsewhere for MR imaging of the liver 
at a dose of 0.05 mmol/kg bodyweight [68]. As noted 
elsewhere [29, 31, 69], the partial hepatobiliary elimi-
nation of gadobenate dimeglumine combined with the 
Fig. 4  Renal abscess. The T2w HASTE sequence (a) shows an inho-
mogeneous cystic lesion (arrow) of the upper pole of the left kidney 
surrounded by a hypointense rim. The lesion is almost isointense to 
the renal cortex and medulla on the unenhanced T1w image (b). After 
injection of 0.05 mmol/kg gadobenate dimeglumine the rim surround-
ing the lesion shows, compared with the renal cortex, delayed but 
homogeneous contrast uptake (c, d), whereas the central areas remain 
hypointense without contrast enhancement. The T1w fs image during 
the equilibrium phase (e) shows persistent enhancement of the rim 
(arrowheads), indicating a wall of inflammatory tissue surrounding 
an abscess formation
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administration of a reduced dose in at-risk patients may 
in part explain the absence of NSF in patients given this 
GBCA.
Our study has several limitations. First, it was a ret-
rospective assessment of consecutive patients rather 
than a prospective evaluation. However, it should be 
noted that our findings for diagnostic performance 
were similar to those obtained elsewhere in a smaller 
prospective study [9]. Second, the evaluation of image 
quality was subjective rather than objective based on 
pre-defined quantitative or qualitative measures of 
enhancement. Finally, DWI was performed in only 29 
patients in our study. Numerous studies have demon-
strated the value of DWI for the improved characteriza-
tion of detected renal neoplasms [15, 16, 57, 70–74]. 
One such study [15] showed that the addition of ADC 
information to CE-MRI findings led to the reclassifi-
cation of 3 of 6 oncocytomas and 2 of 2 multilocular 
cystic nephromas that had originally been misdiag-
nosed as malignant on CE-MRI alone, thereby increas-
ing specificity from 89 to 96 %. The use of gadobenate 
dimeglumine for DWI has previously been demon-
strated in 83 patients with 85 renal masses [75]. In that 
study, a dose of 0.1 mmol/kg gadobenate dimeglumine 
enabled sensitive and specific differentiation of clear 
cell, papillary, and chromophobic RCC. Specifically, 
the sensitivity and specificity values for the differen-
tiation of clear cell from non-clear cell RCC were high 
(95.9 and 94.4 %, respectively), which is particularly 
important given that patients with chromophobic or 
papillary RCC (i.e., not clear cell RCC) have a better 
prognosis than patients with clear cell RCC [76] and 
that these subtypes respond differently to molecularly 
targeted therapies.
In conclusion, our study confirms that gadobenate 
dimeglumine at a dose of 0.05 mmol/kg bodyweight is 
Fig. 5  Multiple oncocytoma. The T2w HASTE sequence (a) shows 
two partially isointense and partially hyperintense lesions (arrows) at 
the upper pole of the left kidney. On the corresponding T1w image 
(b) the lesions are almost isointense to the renal cortex. After injec-
tion of 0.05 mmol/kg gadobenate dimeglumine, the lesions show 
an inhomogeneous hyervascularization in an early arterial phase (c) 
with homogenous contrast uptake in the later phase (d). On the T1w 
fs image (e) in the equilibrium phase the lesions show inhomogene-
ous contrast uptake. Diagnosis based on CE-MRI was multiple RCC; 
however, histology confirmed the lesions to be multiple oncocytoma
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appropriate for MR imaging of the kidney, for the detec-
tion and differential diagnosis of renal neoplasms with high 
diagnostic performance.
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